Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry
radiation directly to tumor cells and not harm normal cells. A peripheral stem cell
transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and
samarium Sm 153 lexidronam pentasodium. Radiation therapy uses high-energy x-rays to kill
tumor cells. Giving samarium Sm 153 lexidronam pentasodium together with a peripheral stem
cell transplant and radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving samarium Sm 153 lexidronam
pentasodium together with autologous stem cell transplant and radiation therapy works in
treating patients with recurrent or refractory, metastatic, or unresectable osteosarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins